NO331734B1 - Anvendelse av et syklopeptid til fremstilling av et medikament for bekjempelse av tumorer ved stralebehandling. - Google Patents
Anvendelse av et syklopeptid til fremstilling av et medikament for bekjempelse av tumorer ved stralebehandling. Download PDFInfo
- Publication number
- NO331734B1 NO331734B1 NO20011308A NO20011308A NO331734B1 NO 331734 B1 NO331734 B1 NO 331734B1 NO 20011308 A NO20011308 A NO 20011308A NO 20011308 A NO20011308 A NO 20011308A NO 331734 B1 NO331734 B1 NO 331734B1
- Authority
- NO
- Norway
- Prior art keywords
- acid
- acceptable salts
- physiologically acceptable
- nme
- cyclo
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 22
- 239000003814 drug Substances 0.000 title claims description 10
- 238000001959 radiotherapy Methods 0.000 title claims description 5
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 102000001189 Cyclic Peptides Human genes 0.000 title 1
- 108010069514 Cyclic Peptides Proteins 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract description 36
- 229940079593 drug Drugs 0.000 claims description 7
- 239000004037 angiogenesis inhibitor Substances 0.000 abstract description 8
- 229940121369 angiogenesis inhibitor Drugs 0.000 abstract description 8
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 abstract description 5
- 230000000973 chemotherapeutic effect Effects 0.000 abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 17
- 239000002246 antineoplastic agent Substances 0.000 description 16
- 229940127089 cytotoxic agent Drugs 0.000 description 16
- 239000002253 acid Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 239000000825 pharmaceutical preparation Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- -1 baltimastat (BB-94) Chemical class 0.000 description 6
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229960002949 fluorouracil Drugs 0.000 description 5
- 102000006495 integrins Human genes 0.000 description 5
- 108010044426 integrins Proteins 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 229940124761 MMP inhibitor Drugs 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 3
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical class ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 3
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229960005243 carmustine Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012154 double-distilled water Substances 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 229960005277 gemcitabine Drugs 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 229940125798 integrin inhibitor Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 2
- KMZHZAAOEWVPSE-UHFFFAOYSA-N 2,3-dihydroxypropyl acetate Chemical compound CC(=O)OCC(O)CO KMZHZAAOEWVPSE-UHFFFAOYSA-N 0.000 description 2
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 235000008191 folinic acid Nutrition 0.000 description 2
- 239000011672 folinic acid Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960001691 leucovorin Drugs 0.000 description 2
- 229960001614 levamisole Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 239000003909 protein kinase inhibitor Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000008347 soybean phospholipid Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- WORSVFBVUCBRIP-VNQPRFMTSA-N (2r,3s)-n-[(2s)-3,3-dimethyl-1-oxo-1-(pyridin-2-ylamino)butan-2-yl]-n'-hydroxy-3-methoxy-2-(2-methylpropyl)butanediamide Chemical compound ONC(=O)[C@@H](OC)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)(C)C)C(=O)NC1=CC=CC=N1 WORSVFBVUCBRIP-VNQPRFMTSA-N 0.000 description 1
- MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- OXQGTIUCKGYOAA-UHFFFAOYSA-N 2-Ethylbutanoic acid Chemical compound CCC(CC)C(O)=O OXQGTIUCKGYOAA-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100022337 Integrin alpha-V Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- JXAGDPXECXQWBC-LJQANCHMSA-N Tanomastat Chemical compound C([C@H](C(=O)O)CC(=O)C=1C=CC(=CC=1)C=1C=CC(Cl)=CC=1)SC1=CC=CC=C1 JXAGDPXECXQWBC-LJQANCHMSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 108010048673 Vitronectin Receptors Proteins 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 229940059756 arava Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 150000003938 benzyl alcohols Chemical class 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000008207 calcium folinate Nutrition 0.000 description 1
- 239000011687 calcium folinate Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- ZXFCRFYULUUSDW-OWXODZSWSA-N chembl2104970 Chemical compound C([C@H]1C2)C3=CC=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2CC(O)=C(C(=O)N)C1=O ZXFCRFYULUUSDW-OWXODZSWSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 208000030499 combat disease Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960005144 gemcitabine hydrochloride Drugs 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- NITYDPDXAAFEIT-DYVFJYSZSA-N ilomastat Chemical compound C1=CC=C2C(C[C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)CC(=O)NO)=CNC2=C1 NITYDPDXAAFEIT-DYVFJYSZSA-N 0.000 description 1
- 229960003696 ilomastat Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Chemical class 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000011707 mineral Chemical class 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- BSIZUMJRKYHEBR-QGZVFWFLSA-N n-hydroxy-2(r)-[[(4-methoxyphenyl)sulfonyl](3-picolyl)amino]-3-methylbutanamide hydrochloride Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N([C@H](C(C)C)C(=O)NO)CC1=CC=CN=C1 BSIZUMJRKYHEBR-QGZVFWFLSA-N 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940026778 other chemotherapeutics in atc Drugs 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-N potassium;hydrate Chemical compound O.[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- YKPYIPVDTNNYCN-INIZCTEOSA-N prinomastat Chemical compound ONC(=O)[C@H]1C(C)(C)SCCN1S(=O)(=O)C(C=C1)=CC=C1OC1=CC=NC=C1 YKPYIPVDTNNYCN-INIZCTEOSA-N 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 239000011782 vitamin Chemical class 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Chemical class 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Oppfinnelsen vedrører et farmasøytisk preparat syklo-(Arg-Gly-Asp-D-Phe-NMe-Val) og/eller et av dets fysiologisk akseptable salter, og minst ett kjemo- terapeutikum og/eller et av dets fysiologisk akseptable salter, og/eller en angiogeneseinhibitor og/eller et av dens fysiologisk akseptable salter.
Description
Oppfinnelsens gjenstand er anvendelse av syklo-(Arg-Gly-Asp-D-Phe-NMe-Val) og/eller et av dets fysiologisk akseptable salter til fremstilling av et medikament for bekjempelse av tumorer ved strålebehandling.
Til grunn for oppfinnelsen lå den oppgave å stille til rådighet bedre behandling for pasienter med tumor.
Denne oppgaven ble løst gjennom oppfinnelsen ifølge foreliggende søknad.
Syklo(Arg-Gly-Asp-D-Phe-NMe-Val) er kjent fra EP 0 770 622 og virker fremfor alt som integrininhibitor, idet det særlig hemmer vekselvirkningen mellom oty-, fø- eller p5-integrinreseptorer og ligander, som f eks bindingen av fibrinogen til avfo-integrinreseptoren. Særlig aktivitet utviser forbindelsen i tilfellet med integrinene avp3, otvP5, a,iibP3 samt av|3i, avp6ogOv|38. Denne virkningen kan påvises f eks etter metoden som er beskrevet av J.W. Smith et al. i J. Biol. Chem. 265,12267-12271 (1990).
Den foreliggende oppfinnelse er å anse som utvelgelsesoppfinnelse i forhold til EP 0 770 622.
IWO 98/14192 er det kjent farmasøytiske preparater som inneholder kombinasjonen av ikke-peptidiske vitronektinreseptorantagonister og kjemoterapeutika. Effekten av antiangiogeneseterapi kombinert med en kjemoterapi er beskrevet av J. Folkman i Nature Medicine 1,27-30 (1995).
WO 97/45447 beskriver fremgangsmåter og sammensetninger for inhibering av otvPs-mediert angiogenese. Fra WO 98/31359 er det kjent sammensetninger med0^3, Ov(35 ellerOv^/otvPsintegrin-antagonister.
Aktiviteten av syklo-(Arg-Gly-Asp-D-Phe-NMe-Val) i kombinasjon med et kjemoterapeutikum kan påvises i Lewis-lungekarsinomsystemet. Lewis-lungekarsinom påvirkes bare utilstrekkelig ved hjelp av vanlige kjemoterapeutika (Y. Kakeji og B.A. Teicher, Invest. New Drugs 15: 39-48 (1997)). Fremgangsmåten for forsinkelse av tumorveksten gjennomføres analogt med Kakeji (F. Mitjans et al., J. Cell Sei. 108: 2825-2838 (1995)).
Som kjemoterapeutikum kan det anvendes et kjemoterapeutikum fra en gruppe bestående av
a) alkylerende midler,
b) antibiotika,
c) antimetabolitter,
d) biologika og immunmodulatorer,
e) hormoner og deres antagonister,
f) sennepsgassderivater,
g) alkaloider,
h) inhibitorer for matriksmetalloproteinaser (MMP-inhibitorer),
i) proteinkinaseinhibitorer,
k) andre.
Alkylerende midler er f eks busulfan, karboplatin, karmustin, cisplatin, syklofosfamid, dakarbazin, ifosfamid eller lomustin. Antibiotika er f eks bleomycin, doksorubicin (adriamycin), idarubicin eller plikamycin.
Antimetabolitter er f eks sulfonamider eller folsyreantagonister, f eks også 5-fluoruracil (5-FU), merkaptopurin, metotreksat eller tioguanin, eller 5-FU med kalsiumfolinat (leukovorin).
Biologika og immunmodulatorer er f eks interferon a2A, interleukin 2 eller levamisol.
Hormoner og deres antagonister er f eks flutamid, goserelin, mitotan eller tamoksifen. Sennepsgassderivater er f eks melfalan, karmustin eller sennepsgass. Alkaloider er f eks taksaner som docetaksel eller paklitaksel, videre etoposid, vinblastin eller vinovelbin.
Under andre kjemoterapeutika skal det forstås slike som ikke kan innordnes i de ovenfor nevnte grupper, som f eks altretamin, kladribin, gemcitabin, leukovorin, levamisol, pentostatin eller irinotekan.
Inhibitorer for matriksmetalloproteinasene (MMP-inhibitorer) som er beskrevet f. eks. også av M. Wittaker et al. i Current Opinion in Drug Discovery & Development 1, 157-164 (1998), er de etterfølgende forbindelser, f eks baltimastat (BB-94), marimastat (BB-2516), BB-3644, ilomastat, metastat, AG-3340, BAY-12-9566, AE-941/neovastat, CGS-27023A, RS-113456, RS-130830, Ro-32-3555, Ro-31-9790, CT-1746, CT-1418, D-1927, D-2163.
Proteinkinaseinhibitorer er f eks beskrevet av G. McMahon et al. i Current Opinion in Drug Discovery & Development 1,131-146 (1998) og av L.M. Strawn et al. i Exp. Opin. Invest. Drugs 7, 553-573 (1998). Eksempler på reseptortyrosinkinase-inhibitorer er: CGP 79787, SU-101 (HWA 486, Leflunomid, Arava), SU-5416, SU-5271 (PD-153035), PD-173074, SU-6668, ZD-1839, CP-358774.
Det kan også anvendes såkalte prodroge-derivater for angiogeneseinhibitorene og/eller kjemoterapeutikaene, det vil si forbindelser som er omdannet f eks med alkyl-eller acylgrupper, sukkere eller oligopeptider, og som hurtig spaltes i organismen til de aktive forbindelsene. Til prodroge-derivatene hører f eks også kjemoterapeutikumet kapecitabin, som utgjør prodrogen for 5-FU, slik dette er beskrevet f eks i Inpharma nr. 1142,13-14(1998).
Anvendelse av gemcitabin ved tumorbehandlingen er beskrevet f eks av B.J. Braakhuis et al. i Semin-Oncol. 1995 Aug; 22(4 Suppl. 11): 42-6 eller av R.M. Mohammad et al. i Pancreas 1998 Jan; 16 (1): 19-25.
Ytterligere angiogeneseinhibitorer er beskrevet f eks i tabell 1 i WO 9741844. avp3- og avp5-integrininhibitorer er f eks de i EP 0 770 622 nevnte forbindelser.
Et farmasøytisk preparat kan fremstilles idet man bringer syklo-(Arg-Gly-Asp-D-Phe-NMe-Val) og/eller et av dets fysiologisk akseptable salter og minst ett kjemoterapeutikum og/eller et av dets fysiologisk akseptable salter og/eller en angiogeneseinhibitor og/eller et av dens fysiologisk akseptable salter sammen med minst ett fast, flytende eller halvflytende bærer- eller hjelpestoff i en egnet doseringsform. De således erholdte preparater kan anvendes som legemidler innen human- eller veterinær-medisinen, særlig ved behandling av tumorer. Som bærerstoffer kommer det på tale med organiske eller uorganiske stoffer som egner seg for den enterale (f eks orale, sublinguale eller rektale), parenterale eller topiske (f eks transdermale) applikasjon, og som ikke reagerer med forbindelsene, f eks vann, planteoljer, benzylalkoholer, polyetylenglykoler, glyserolacetat og andre fettsyreglyserider, gelatin, soyalecitin, karbohydrater som laktose eller stivelse, magnesiumstearat, talkum, cellulose. For oral anvendelse tjener særlig tabletter, drasjeer, kapsler, siruper, safter eller dråper, for rektal anvendelse suppositorier, for parenteral applikasjon oppløsninger, fortrinnsvis olje- eller vannoppløsninger, videre suspensjoner, emulsjoner eller implantater, for topisk anvendelse salver, kremer eller plaster. Den aktive forbindelse kan også lyofiliseres og det erholdte lyofilisat anvendes f eks til fremstilling av injeksjonspreparater. Preparatene kan være sterilisert og/eller inneholde hjelpestoffer som konserverings-, stabiliserings- og/eller fuktemidler, emulgatorer, salter for påvirkning av det osmotiske trykk, bufferstoffer, farge- og/eller aromastoffer. De kan også inneholde ytterligere aktive forbindelser, f eks andre blodtrykksenkende eller diuretisk aktive forbindelser, men også vitaminer og/eller mineralsalter, særlig slike som begunstiger de metabolske prosesser.
Slike preparater kan anvendes ved bekjempelse av patologisk angiogene sykdommer, tromboser, hjerteinfarkt, koronare hjertesykdommer, arteriosklerose, tumorer, osteoporose, betennelser og infeksjoner. Som regel anvendes de til tumorbekjempelse, også til inhibering av tumorveksten eller av tumormetastaser.
Syklo-(Arg-Gly-Asp-D-Phe-NMe-Val) kan anvendes i slike kombinasjons-preparater som anvendes til bekjempelse av sykdommer hvor Ov-integriner, særligOvfø og av(35spiller en rolle, hvorved deres hemming er en del av terapien.
Syklo-(Arg-Gly-Asp-D-Phe-NMe-Val) kan anvendes innen tumorterapien, også i kombinasjon med en annen angiogeneseinhibitor,
a) ved kirurgisk fjerning av en tumor,
b) ved strålingsterapi,
c) ved fotodynamisk terapi,
d) sammen med monoklonale antistoffer mot tumorselektive epitoper,
e) sammen med fusjonsproteiner,
f) sammen med peptidvaksiner og
g) ved genterapi.
Doseringen av syklo-(Arg-Gly-Asp-D-Phe-NMe-Val) hhv. dets salter, og også kjemoterapeutikaene og/eller angiogeneseinhibitorene ligger fortrinnsvis mellom ca 0,1 og 100 mg, særlig mellom 0,2 og 20 mg, helt spesielt mellom 0,1 og 10 mg per doseringsenhet. Den daglige dosering ligger fortrinnsvis mellom ca 0,001 og 1, særlig mellom 0,002 og 0,2 mg/kg kroppsvekt.
Under en kjemoterapi kan peptider også gis i en dosering på 1-10 mg/kg 2 ganger per uke. Kjemoterapeutikaene kan f eks også administreres ved en dosering på 1-10 mg/kg en gang per uke i alt i 3-4 uker. De spesielle doser for hver pasient avhenger imidlertid av de forskjelligste faktorer, f eks av aktiviteten av den anvendte spesielle forbindelse, av alderen, kroppsvekten, den generelle helsetilstand, arv, av kost, av administreringstidspunkt og -vei, av utskillingshastighet, legemiddelkombinasjon og alvorligheten av den enkelte sykdom som behandlingen gjelder for. Den orale applikasjon er foretrukket.
Oppfinnelsens gjenstand er således anvendelse av syklo-(Arg-Gly-Asp-D-Phe-NMe-Val) og/eller et av dets fysiologisk akseptable salter til fremstilling av et medikament for bekjempelse av tumorer ved strålebehandling..
Anvendelse av de beskrevne farmasøytisk preparater for bekjempelse av patologisk angiogene sykdommer, tromboser, hjerteinfarkt, koronare hjertesykdommer, arterioskle-rose, tumorer, osteoporose, betennelser og infeksjoner, er også mulig..
Anvendelse av syklo-(Arg-Gly-Asp-D-Phe-NMe-Val) og/eller et av dets fysiologisk akseptable salter etter hverandre eller i fysikalsk kombinasjon med et kjemoterapeutikum og/eller et av dets fysiologisk akseptable salter og/eller en angiogeneseinhibitor og/eller et av dens fysiologisk akseptable salter til fremstilling av et legemiddel for bekjempelse av tumorer, er også mulig.
Anvendelse av syklo-(Arg-Gly-Asp-D-Phe-NMe-Val) og/eller et av dens fysiologisk akseptable salter etter hverandre og/eller i fysikalsk kombinasjon med et kjemoterapeutikum og/eller et av dets fysiologisk akseptable salter til fremstilling av et legemiddel for bekjempelse av tumorer, er også mulig.
Anvendelse av syklo-(Arg-Gly-Asp-D-Phe-NMe-Val) og/eller et av dets fysiologisk akseptable salter etter hverandre i fysikalsk kombinasjon med et kjemoterapeutikum og/eller et av dets fysiologisk akseptable salter for bekjempelse av tumorer, er også mulig.
Bestanddelene i de farmasøytiske preparatene administreres fortrinnsvis i kombinasjon. De kan imidlertid også administreres hver for seg, samtidig eller etter hverandre.
Det kan også anvendes et sett bestående av atskilte pakninger av
(a) en aktiv mengde av syklo-(Arg-Gly-Asp-D-Phe-NMe-Val) og (b) en aktiv mengde av et kjemoterapeutikum.
Settet inneholder egnede beholdere, som bokser eller kartonger, individuelle flasker, poser eller ampuller. Settet kan f eks inneholde separate ampuller hvor en aktiv mengde av et syklo-(Arg-Gly-Asp-D-Phe-NMe-Val) og kjemoterapeutikumet foreligger oppløst eller i lyofilisert form.
Fra WO 9814192 er det kjent forskjellige biologiske tester som er egnet til å bestemme konsentrasjonen av forbindelsene som fremkaller en farmakologisk effekt.
Syklo-(Arg-Gly-Asp-D-Phe-NMe-Val), kjemoterapeutikumet eller angigeneseinhibitoren kan, når det foreligger en syrefunksjon, overføres med en base til det tilhørende syreaddisjonssalt, f eks ved omsetning av ekvivalente mengder av syren og basen i et inert oppløsningsmiddel som etanol, og påfølgende inndamping. For denne omsetningen kommer det særlig på tale med baser som gir fysiologisk akseptable salter. Således kan en syre omdannes med en base (f eks natrium- eller kaliumhydridoksid eller -karbonat) til det tilsvarende metall-, særlig alkalimetall eller jordalkalimetallsalt til det tilsvarende ammoniumsalt.
På den annen side kan en basisk funksjon overføres til det tilhørende syreaddisjonssalt, f eks ved omsetning av ekvivalente mengder av basen og syren i et inert oppløsningsmiddel som etanol, og med påfølgende inndamping. For denne inndampingen kommer det særlig på tale med syrer som gir fysiologisk akseptable salter. Således kan det anvendes uorganiske syrer, f eks svovelsyre, salpetersyre, hydrogenhalogensyrer som saltsyre eller hydrogenbromsyre, fosforsyrer som ortofosforsyre, sulfaminsyre, videre organiske syrer, særlig alifatiske, alisykliske, aralifatiske, aromatiske eller heterosykliske, én- eller flerbasiske karboksyl-, sulfon-eller svovelsyrer, f eks maursyre, eddiksyre, propionsyre, pivalinsyre, dietyleddiksyre, malonsyre, ravsyre, pimelinsyre, fumarsyre, maleinsyre, melkesyre, vinsyre, eplesyre, sitronsyre, glukonsyre, askorbinsyre, nikotinsyre, isonikotinsyre, metan- eller etansulfonsyre, etandisulfonsyre, 2-hydroksyetansulfonsyre, benzensulfonsyre, p-toluensulfonsyre, naftalen-mono- og/eller disulfonsyrer, laurylsvovelsyre. Salter med fysiologisk ikke akseptable syrer, f eks pikrater, kan anvendes til isolering og/eller rensing av forbindelsene med formel (I).
Et farmasøytisk preparat som inneholder en0^3- og/eller en av(35-integrininhibitor og/eller et av dens fysiologisk akseptable salter og minst én MMP-inhibitor og/eller et av dens fysiologisk akseptable salter, samt et farmasøytisk preparat som inneholder en 0^3- og/eller en av(35-integrininhibitor og/eller et av dens fysiologisk akseptable salter og minst én tyrosinkinaseinhibitor og/eller et av dens fysiologisk akseptable salter, er også mulig.
FortrukneOvfø- og avp5-integrininhibitorer er f eks beskrevet i EP 0 770 622, EP 0 710 657, EP 0 820 988, EP 0 820 991, WO 94/12181, WO 94/08577, EP 0 518 586, WO 95/32710, WO 96/00574, WO 96/00730 eller i DE 198 50 131.
Blant MMP-inhibitorene og tyrosinkinaseinhibitorene er de ovenfor nevnte foretrukne.
Eksempel på tester for kombinasjonsterapi:
Retardasjon av tumorvekst analogt med Kakeji (F. Mitjans et al., J. Cell Sei. 108: 2825-2838(1995)): Lewis-lungekarsinomceller (2 x 10E6) ble injisert i 8-10 uker gamle C57BL-mus. Fra den fjerde dag ble syklo-(Arg-Gly-Asp-D-Phe-NMe-Val) (30 mg/kg) administrert i.p daglig. Tumorveksten ble målt daglig (B.A. Teicher et al., Int. J. Cancer 57: 920-925 (1994)). Dersom tumorene nådde et bestemt volum på ca 100 mm<3>, begynte man på dag 7 etter tumorinokulasjonen forskjellige cytotoksiske kombinasjonsterapier gjennom intraperitoneal injeksjon. Eksempler: 5-fluoruracil (30 mg/kg) eller adriamycin (1,8 mg/kg) ble gitt daglig fra dag 7 til 11. Syklofosfamid (150 mg/kg), karmustin (15 mg/kg) eller gemcitabin (2,5 mg/kg) ble gitt på dag 7, 9 og 11. Cisplatin (10 mg/kg) ble gitt på dag 7. Tumorene ble målt tre ganger i uken inntil et volum på ca 500 mm<3>var nådd. Retardasjonen av tumorvekst ble beregnet som den tid som en enkelt tumor trengte for å nå 500 mm sammenlignet med ubehandlede kontroller.
De etterfølgende eksempler vedrører farmasøytiske preparater:
Eksempel A: Injeksjonsglass
En oppløsning av 100 g syklo-(Arg-Gly-Asp-D-Phe-NMe-Val) og/eller et av dens fysiologisk akseptable salter, 100 g av kjemoterapeutikumet og 5 g dinatriumhydrogenfosfat innstilles i 6 1 dobbeltdestillert vann med 2 n saltsyre på pH 6,5, det sterilfiltreres, fylles i injeksjonsglass, lyofiliseres under sterile betingelser og lukkes sterilt. Hvert injeksjonsglass inneholder 5 mg av den aktive forbindelse.
Eksempel B: Suppositorier
Man smelter en blanding av syklo-(Arg-Gly-Asp-D-Phe-NMe-Val) og/eller et av dets fysiologisk akseptable salter, 20 g av kjemoterapeutikumet sammen med 100 g soyalecitin og 1400 g kakaosmør, heller i former og lar det avkjøles. Hvert suppositorium inneholder 20 mg av den aktive forbindelse.
Eksempel C: Oppløsning
Det lages en oppløsning av 20 g syklo-(Arg-Gly-Asp-D-Phe-NMe-Val) og/eller et av dets fysiologisk akseptable salter, 1 g av kjemoterapeutikumet, 9,38 g NaH2P042 H20, 28,48 Na2HP0412 H20 og 0,1 g benzalkoniumklorid i 940 ml dobbeltdestillert vann. Det innstilles på pH 6,8 og fylles opp til 1 1 og steriliseres ved bestråling. Denne oppløsningen kan anvendes i form av øyedråper.
Eksempel D: Salve
Man blander 500 mg syklo-(Arg-Gly-Asp-D-Phe-NMe-Val) og/eller et av dets fysiologisk akseptable salter, 500 mg av kjemoterapeutikumet med 99,5 g vaselin under aseptiske betingelser.
Eksempel E: Tabletter
En blanding av 1 kg syklo-(Arg-Gly-Asp-D-Phe-NMe-Val) og/eller et av dets fysiologisk akseptable salter, 1 kg av kjemoterapeutikumet, 4 kg laktose, 1,2 kg potetstivelse, 0,2 kg talkum og 0,1 kg magnesiumstearat presses på vanlig måte til
tabletter, slik at hver tablett inneholder 10 mg aktiv forbindelse.
Eksempel F: Drasjeer
Analogt med eksempel E presses tabletter som deretter belegges på vanlig måte med et belegg av sakkarose, potetstivelse, talkum, tragant og farvestoff.
Eksempel G: Kapsler
2 kg syklo-(Arg-Gly-Asp-D-Phe-NMe-Val) og/eller et av dets fysiologisk akseptable salter, 2 kg av kjemoterapeutikumet fylles på vanlig måte i hardgelatinkapsler, slik at hver kapsel inneholder 20 mg av den aktive forbindelse.
Eksempel H: Ampuller
En oppløsning av 1 kg syklo-(Arg-Gly-Asp-D-Phe-NMe-Val) og/eller et av dets fysiologisk akseptable salter, 1 kg av kjemoterapeutikumet sterilfiltreres i 601 dobbeltdestillert vann, fylles i ampuller, det lyofiliseres under sterile betingelser og lukkes sterilt. Hver ampulle inneholder 10 mg av den aktive forbindelse.
Eksempel I: Sett
Preparat (sett) for parenteral anvendelse.
Preparatet inneholder 500 mg syklo-(Arg-Gly-Asp-D-Phe-NMe-Val) og/eller et av dets fysiologisk akseptable salter og 500 mg gemcitabinhydroklorid, og fremstilles på følgende måte: 500 mg av begge forbindelsene oppløses i 40 ml destillert vann. Oppløsningen filtreres under sterile betingelser og fylles i 10 ml ampuller og lyofiliseres. For intravenøs eller intramuskulær injeksjon tilsettes 10 ml 5 %-ig vandig dekstrose.
Claims (1)
1. Anvendelse av syklo(Arg-Gly-Asp-D-Phe-NMe-Val) og/eller et av dets fysiologisk akseptable salter til fremstilling av et medikament for bekjempelse av tumorer ved strålebehandling.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19842415A DE19842415A1 (de) | 1998-09-16 | 1998-09-16 | Pharmazeutische Zubereitung |
PCT/EP1999/006654 WO2000015244A2 (de) | 1998-09-16 | 1999-09-09 | Pharmazeutische zubereitung enthaltend ein cyclo-peptide und ein chemotherapeutikum oder einen angiogeneseinhibitor |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20011308D0 NO20011308D0 (no) | 2001-03-15 |
NO20011308L NO20011308L (no) | 2001-03-15 |
NO331734B1 true NO331734B1 (no) | 2012-03-12 |
Family
ID=7881169
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20011308A NO331734B1 (no) | 1998-09-16 | 2001-03-15 | Anvendelse av et syklopeptid til fremstilling av et medikament for bekjempelse av tumorer ved stralebehandling. |
Country Status (31)
Country | Link |
---|---|
US (1) | US6683051B1 (no) |
EP (2) | EP1113809B1 (no) |
JP (2) | JP2002524526A (no) |
KR (1) | KR100703253B1 (no) |
CN (2) | CN1201812C (no) |
AR (2) | AR022382A1 (no) |
AT (2) | ATE292470T1 (no) |
AU (1) | AU765073B2 (no) |
BR (1) | BR9913737A (no) |
CA (1) | CA2344151A1 (no) |
CO (1) | CO5140070A1 (no) |
CZ (1) | CZ302908B6 (no) |
DE (3) | DE19842415A1 (no) |
DK (2) | DK1466615T3 (no) |
ES (2) | ES2327331T3 (no) |
HU (1) | HUP0103521A3 (no) |
ID (1) | ID29226A (no) |
IL (2) | IL141516A0 (no) |
MY (1) | MY129572A (no) |
NO (1) | NO331734B1 (no) |
NZ (1) | NZ510040A (no) |
PE (1) | PE20001046A1 (no) |
PL (1) | PL201902B1 (no) |
PT (2) | PT1466615E (no) |
RU (1) | RU2227041C2 (no) |
SI (1) | SI1113809T1 (no) |
SK (1) | SK287012B6 (no) |
TR (1) | TR200100765T2 (no) |
TW (1) | TW576744B (no) |
WO (1) | WO2000015244A2 (no) |
ZA (1) | ZA200103073B (no) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7740841B1 (en) * | 2000-01-28 | 2010-06-22 | Sunnybrook Health Science Center | Therapeutic method for reducing angiogenesis |
BR0116575A (pt) * | 2001-01-09 | 2004-01-06 | Merck Patent Gmbh | Terapia combinada que usa inibidores de tirosina cinase receptora e inibidores de angiogênese |
WO2003074045A1 (fr) * | 2002-03-05 | 2003-09-12 | Eisai Co., Ltd. | Agent antitumoral comprenant une combinaison d'un compose heterocyclique contenant un sulfamide et d'un inhibiteur d'angiogenese |
DK1734996T3 (da) * | 2004-04-02 | 2013-06-10 | Univ California | Fremgangsmåder og sammensætninger til behandling og forebyggelse af sygdom, der er associeret med alfa v beta 5-integrin |
CN103463630A (zh) * | 2005-11-02 | 2013-12-25 | 杜克大学 | 同时的化学疗法和免疫疗法 |
EP1973569B1 (en) * | 2006-01-18 | 2013-05-22 | Merck Patent GmbH | Specific therapy using integrin ligands for treating cancer |
US20110165150A1 (en) * | 2006-01-18 | 2011-07-07 | Merck Patent Gmbh | Isolated organ perfusion combination therapy of cancer |
BRPI0815567B8 (pt) | 2007-07-17 | 2021-05-25 | Merck Patent Gessellschaft Mit Beschraenkter Haftung | anticorpos híbridos anti-alfa v-integrina projetados, proteína de fusão e composição farmacêutica |
US20100069302A1 (en) | 2007-07-18 | 2010-03-18 | Stefan Krueger | Specific therapy and medicament using integrin ligands for treating cancer |
WO2010051667A1 (zh) * | 2008-11-10 | 2010-05-14 | 复旦大学 | 一种环肽纳米管药物组合物及其应用 |
MX2011005256A (es) * | 2008-11-20 | 2011-05-31 | Merck Patent Gmbh | Nueva terapia y medicamento que usa liganodos de integrina para tratamiento de cancer. |
JP2012528079A (ja) | 2009-05-25 | 2012-11-12 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌を治療するためのインテグリンリガンドの連続投与 |
KR101752515B1 (ko) | 2009-07-24 | 2017-06-29 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Avb5 인테그린과 결부된 질환의 치료 및 예방을 위한 방법 및 조성물 |
PE20121359A1 (es) | 2009-12-10 | 2012-10-15 | Merck Patent Gmbh | Composicion farmaceutica que comprende oligopeptidos |
CA2805338A1 (en) | 2010-07-16 | 2012-01-19 | Merck Patent Gmbh | Peptide for use in the treatment of breast cancer and/or bone metastases |
WO2012069149A1 (en) | 2010-11-23 | 2012-05-31 | Merck Patent Gmbh | Solution comprising cyclic oligopeptides |
JP6320042B2 (ja) | 2011-02-11 | 2018-05-09 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | 前立腺癌治療のための抗アルファ−vインテグリン抗体 |
WO2012110200A1 (en) * | 2011-02-18 | 2012-08-23 | Merck Patent Gmbh | Cyclic peptide cyclo (l -arginyl - glycyl - l -aspartyl - d - phenylalanyl - n-methyl - l -valyl), compositions thereof, and use thereof in methods for treating graft -versus - host disease |
ES2720477T3 (es) | 2011-06-09 | 2019-07-22 | Merck Patent Gmbh | Tratamiento de cánceres y metástasis con suspensiones de Cilengitide en portador |
WO2013130775A1 (en) * | 2012-03-01 | 2013-09-06 | Dizerega, Gere, S. | Methods for treating patients undergoing multi-cycle chemotherapy |
CN103333227B (zh) * | 2013-06-07 | 2015-10-07 | 东南大学 | 转移肿瘤缺失蛋白小分子环肽抑制剂及其制备方法与应用 |
US20190242908A1 (en) | 2016-09-08 | 2019-08-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating nephrotic syndrome |
JP2019208422A (ja) * | 2018-06-04 | 2019-12-12 | コリア・インスティテュート・オブ・サイエンス・アンド・テクノロジー | ヒアルロニダーゼを含む新規な組換えエキソソーム及びその用途 |
GB201911816D0 (en) * | 2019-08-16 | 2019-10-02 | Univ London Queen Mary | Treatment |
GB202103122D0 (en) * | 2021-03-05 | 2021-04-21 | Univ London Queen Mary | Treatment |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04367367A (ja) | 1991-06-11 | 1992-12-18 | Nkk Corp | ロータリノズル |
AU674553B2 (en) | 1992-10-14 | 1997-01-02 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
WO1994012181A1 (en) | 1992-12-01 | 1994-06-09 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
AU701776B2 (en) | 1994-05-27 | 1999-02-04 | Merck & Co., Inc. | Compounds for inhibiting osteoclast-mediated bone resorption |
PL318199A1 (en) | 1994-06-29 | 1997-05-26 | Smithkline Beecham Corp | Antagonists of vitronectin receptors |
JPH10504807A (ja) | 1994-06-29 | 1998-05-12 | スミスクライン・ビーチャム・コーポレイション | ビトロネクチン受容体拮抗剤 |
DK0710657T3 (da) | 1994-11-02 | 1999-05-25 | Merck Patent Gmbh | Adhæsionsreceptor-antagonister |
DE19534177A1 (de) * | 1995-09-15 | 1997-03-20 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
DE19548709A1 (de) * | 1995-12-23 | 1997-07-03 | Merck Patent Gmbh | Tyrosinderivate |
JPH09208571A (ja) * | 1996-02-02 | 1997-08-12 | Takeda Chem Ind Ltd | アルキリデンシクロヘキサン誘導体 |
WO1997041844A1 (en) * | 1996-05-09 | 1997-11-13 | Alcon Laboratories, Inc. | Combinations of angiostatic compounds |
US5919815A (en) * | 1996-05-22 | 1999-07-06 | Neuromedica, Inc. | Taxane compounds and compositions |
PL330241A1 (en) * | 1996-05-31 | 1999-05-10 | Scripps Research Inst | Methods of and compositions useful in inhibiting angiogenesis |
JPH1081631A (ja) * | 1996-07-17 | 1998-03-31 | Takeda Chem Ind Ltd | 癌転移または再発抑制剤 |
DE19629816A1 (de) | 1996-07-24 | 1998-01-29 | Hoechst Ag | Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten |
DE19629817A1 (de) | 1996-07-24 | 1998-01-29 | Hoechst Ag | Neue Imino-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten |
UA60311C2 (uk) * | 1996-10-02 | 2003-10-15 | Смітклайн Бічам Корпорейшн | Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція |
CA2277273C (en) * | 1997-01-17 | 2008-03-25 | Merck & Co., Inc. | Integrin antagonists |
DE19850131A1 (de) | 1998-10-30 | 2000-05-04 | Merck Patent Gmbh | Chromenon- und Chromanonderivate |
-
1998
- 1998-09-16 DE DE19842415A patent/DE19842415A1/de not_active Withdrawn
-
1999
- 1999-09-09 DE DE59915033T patent/DE59915033D1/de not_active Expired - Lifetime
- 1999-09-09 IL IL14151699A patent/IL141516A0/xx unknown
- 1999-09-09 RU RU2001110104/15A patent/RU2227041C2/ru not_active IP Right Cessation
- 1999-09-09 AT AT99969031T patent/ATE292470T1/de active
- 1999-09-09 NZ NZ510040A patent/NZ510040A/en not_active IP Right Cessation
- 1999-09-09 EP EP99969031A patent/EP1113809B1/de not_active Expired - Lifetime
- 1999-09-09 AT AT04006076T patent/ATE432707T1/de active
- 1999-09-09 TR TR2001/00765T patent/TR200100765T2/xx unknown
- 1999-09-09 WO PCT/EP1999/006654 patent/WO2000015244A2/de active IP Right Grant
- 1999-09-09 CA CA002344151A patent/CA2344151A1/en not_active Abandoned
- 1999-09-09 CZ CZ20010932A patent/CZ302908B6/cs not_active IP Right Cessation
- 1999-09-09 CN CNB998133876A patent/CN1201812C/zh not_active Expired - Fee Related
- 1999-09-09 AU AU59758/99A patent/AU765073B2/en not_active Ceased
- 1999-09-09 ES ES04006076T patent/ES2327331T3/es not_active Expired - Lifetime
- 1999-09-09 CN CNB2004100834955A patent/CN100352494C/zh not_active Expired - Fee Related
- 1999-09-09 PL PL348026A patent/PL201902B1/pl not_active IP Right Cessation
- 1999-09-09 ES ES99969031T patent/ES2241363T3/es not_active Expired - Lifetime
- 1999-09-09 PT PT04006076T patent/PT1466615E/pt unknown
- 1999-09-09 DK DK04006076T patent/DK1466615T3/da active
- 1999-09-09 ID IDW20010746A patent/ID29226A/id unknown
- 1999-09-09 DE DE59911881T patent/DE59911881D1/de not_active Expired - Lifetime
- 1999-09-09 SI SI9930792T patent/SI1113809T1/xx unknown
- 1999-09-09 US US09/787,374 patent/US6683051B1/en not_active Expired - Lifetime
- 1999-09-09 PT PT99969031T patent/PT1113809E/pt unknown
- 1999-09-09 HU HU0103521A patent/HUP0103521A3/hu unknown
- 1999-09-09 DK DK99969031T patent/DK1113809T3/da active
- 1999-09-09 BR BR9913737-2A patent/BR9913737A/pt not_active Application Discontinuation
- 1999-09-09 SK SK337-2001A patent/SK287012B6/sk not_active IP Right Cessation
- 1999-09-09 KR KR1020017003238A patent/KR100703253B1/ko not_active IP Right Cessation
- 1999-09-09 EP EP04006076A patent/EP1466615B1/de not_active Expired - Lifetime
- 1999-09-09 JP JP2000569828A patent/JP2002524526A/ja active Pending
- 1999-09-13 PE PE1999000926A patent/PE20001046A1/es not_active Application Discontinuation
- 1999-09-13 MY MYPI99003955A patent/MY129572A/en unknown
- 1999-09-15 AR ARP990104617A patent/AR022382A1/es not_active Application Discontinuation
- 1999-09-16 TW TW088116003A patent/TW576744B/zh not_active IP Right Cessation
- 1999-09-16 CO CO99058733A patent/CO5140070A1/es unknown
-
2001
- 2001-02-19 IL IL141516A patent/IL141516A/en not_active IP Right Cessation
- 2001-03-15 NO NO20011308A patent/NO331734B1/no not_active IP Right Cessation
- 2001-04-12 ZA ZA200103073A patent/ZA200103073B/en unknown
-
2010
- 2010-09-15 AR ARP100103356A patent/AR078175A2/es not_active Application Discontinuation
-
2011
- 2011-08-12 JP JP2011176480A patent/JP2011252012A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO331734B1 (no) | Anvendelse av et syklopeptid til fremstilling av et medikament for bekjempelse av tumorer ved stralebehandling. | |
KR102357526B1 (ko) | 이식편 대 숙주 질환의 치료 및 예방 방법 | |
US20180022730A1 (en) | Small-molecule inhibitors targeting discoidin domain receptor 1 and uses thereof | |
MX2008012728A (es) | Combinaciones de agentes terapeuticos para el tratamiento de cancer. | |
UA114414C2 (uk) | Введення інгібітору ферменту, що активує nedd8, і гіпометилуючого засобу | |
CA2866021C (en) | Procaspace 3 activation by pac-1 combination therapy | |
JP2016026145A (ja) | オキサゾリジノン含有二量体化合物、組成物、ならびに作製および使用方法 | |
CA2616517A1 (en) | Abl kinase inhibition | |
MX2011000511A (es) | Uso de derivados de pirimidil-amino-benzamida para el tratamiento de fibrosis. | |
MX2008012716A (es) | Combinaciones de agentes terapeuticos para el tratamiento de cancer. | |
CA3199157A1 (en) | Methods of treating diseases and disorders | |
JP2018502863A (ja) | 白血病の治療のための4−(4−フルオロ−2−メトキシフェニル)−n−{3−[(s−メチルスルホンイミドイル)メチル]フェニル}−1,3,5−トリアジン−2−アミンの使用 | |
MXPA01002735A (en) | Pharmaceutical preparation containing a cyclopeptide and a chemotherapeutic agent or an angiogenesis inhibitor | |
ES2289305T3 (es) | Medicamento para el tratamiento del "sindrome de la respuesta inflamatoria sistemica". | |
TW202313039A (zh) | Pm14用途與方案 | |
WO2020102304A1 (en) | Combination of a kinase inhibitor and an electrolyte, compositions and methods comprising the same | |
UA103917C2 (uk) | Застосування sns-595 для лікування суб'єктів з онкологічними захворюваннями, які мають знижену активність brca2 | |
JP2005520820A (ja) | (a)c−ablキナーゼ活性のATP−競合阻害剤と(b)2種またはそれ以上の他の抗腫瘍薬の組合わせ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application | ||
MM1K | Lapsed by not paying the annual fees |